Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
The average one-year price target for Genprex, Inc. is $8.92. The forecasts range from a low of $7.58 to a high of $10.50. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings.
Based on 11 Wall Street analysts offering 12 month price targets for Genpact in the last 3 months. The average price target is $39.00 with a high forecast of $43.00 and a low forecast of $29.00.
On average, Wall Street analysts predict that Kirkland's's share price could reach $4.50 by Sep 6, 2025. The average Kirkland's stock price prediction forecasts a potential upside of 194.12% from the current KIRK share price of $1.53.
On average, Wall Street analysts predict that Paymentus Holdings's share price could reach $23.63 by Aug 20, 2025. The average Paymentus Holdings stock price prediction forecasts a potential upside of 12.07% from the current PAY share price of $21.08. What is PAY's Earnings Per Share (EPS) forecast for 2024-2026?
The Class A shares of Berkshire Hathaway command the top position, with an impressive stock price of over half a million dollars. Swiss chocolatier Chocoladefabriken Lindt & Sprüngli AG holds steady in second place with its six-figure stock price of CHF 123,433.
Neurocrine has a consensus rating of Strong Buy which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings. The average price target for Neurocrine is $168.00. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
GE Aerospace has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings. The average price target for GE Aerospace is $198.58. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The average price target for MaxCyte Inc is $7.26. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $7.26 ,the lowest forecast is $7.26. The average price target represents 83.46% Increase from the current price of $3.96.
Address: Apt. 915 481 Sipes Cliff, New Gonzalobury, CO 80176
Phone: +6773780339780
Job: Sales Executive
Hobby: Gaming, Jogging, Rugby, Video gaming, Handball, Ice skating, Web surfing
Introduction: My name is Carmelo Roob, I am a modern, handsome, delightful, comfortable, attractive, vast, good person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.
